Massimo G Roncalli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6176955/publications.pdf

Version: 2024-02-01

20759 23472 13,557 162 60 111 citations h-index g-index papers 165 165 165 16965 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology, 2009, 49, 658-664.	3.6	722
2	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86.	5.8	543
3	Increased <i>MET</i> Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2009, 27, 1667-1674.	0.8	530
4	Identifying and Targeting <i>ROS1</i> Gene Fusions in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4570-4579.	3.2	405
5	Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology, 2007, 45, 725-734.	3.6	379
6	A Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 445-453.	2.5	365
7	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. Cell, 2015, 160, 700-714.	13.5	334
8	Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1166-1175.	2.5	302
9	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology, 2009, 20, 298-304.	0.6	286
10	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 746-754.	1.8	280
11	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology, 2014, 60, 1983-1992.	3.6	268
12	cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	3.6	244
13	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology, 2008, 19, 717-723.	0.6	243
14	Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues. American Journal of Clinical Pathology, 2008, 129, 899-906.	0.4	229
15	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. Journal of Immunology, 2009, 182, 4415-4422.	0.4	227
16	CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncology, The, 2009, 10, 877-884.	5.1	226
17	Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clinical Cancer Research, 2007, 13, 3831-3839.	3.2	221
18	Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study. Gastroenterology, 1995, 108, 812-817.	0.6	219

#	Article	IF	CITATIONS
19	The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: Implications for diagnosis and classification. Hepatology, 1999, 30, 1174-1178.	3.6	195
20	YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of Hepatology, 2014, 61, 1088-1096.	1.8	191
21	Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. Journal of Hepatology, 2003, 39, 208-214.	1.8	182
22	Lung cancer screening with spiral CT. Lung Cancer, 2008, 59, 355-363.	0.9	179
23	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncolmmunology, 2016, 5, e1085147.	2.1	169
24	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer, 2008, 99, 83-89.	2.9	167
25	The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2008, 68, 9060-9069.	0.4	153
26	p53 protein accumulation and p53 gene mutation in esophageal carcinoma., 1997, 79, 425-432.		145
27	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	2.3	141
28	The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut, 2010, 59, 197-206.	6.1	138
29	Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology, 2007, 45, 968-976.	3.6	133
30	Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer, 2009, 9, 125.	1.1	130
31	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	1.8	130
32	Distribution of Endothelin-like Immunoreactivity and mRNA in the Developing and Adult Human Lung. American Journal of Respiratory Cell and Molecular Biology, 1991, 4, 50-58.	1.4	129
33	A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology, 2012, 55, 1776-1786.	3.6	127
34	Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer, 2007, 109, 915-923.	2.0	124
35	Renal Angiomyolipoma With Epithelioid Sarcomatous Transformation and Metastases. American Journal of Surgical Pathology, 2000, 24, 889-894.	2.1	123
36	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961.	3.3	122

#	Article	IF	CITATIONS
37	Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma. Hepatology, 2020, 71, 183-195.	3.6	119
38	Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology, 2002, 36, 427-432.	3.6	108
39	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. Journal of Experimental Medicine, 2020, 217, .	4.2	99
40	Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin. Clinical Cancer Research, 2011, 17, 2581-2590.	3.2	94
41	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncolmmunology, 2017, 6, e1342918.	2.1	90
42	MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver International, 2012, 32, 772-782.	1.9	89
43	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Research, 2016, 18, 121.	2.2	89
44	Contrast-Enhanced Intraoperative Ultrasonography During Hepatectomies for Colorectal Cancer Liver Metastases. Journal of Gastrointestinal Surgery, 2005, 9, 1148-1154.	0.9	83
45	Role of the stromal-derived factor-1 (SDF-1)–CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. Journal of Hepatology, 2012, 57, 813-820.	1.8	82
46	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology, 2008, 19, 1605-1612.	0.6	81
47	HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clinical Cancer Research, 2003, 9, 3645-52.	3.2	81
48	High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm. Gastrointestinal Endoscopy, 2013, 77, 96-101.	0.5	80
49	Contrast-enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology, 2001, 34, 1109-1112.	3.6	79
50	Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology, 2011, 53, 1549-1557.	3.6	77
51	Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. British Journal of Cancer, 2006, 95, 1101-1107.	2.9	73
52	Molecular Changes in Hepatocellular Dysplastic Nodules on Microdissected Liver Biopsies. Hepatology, 2000, 32, 942-946.	3.6	72
53	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology, 2010, 21, 562-567.	0.6	70
54	Histopathological classification of hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S228-S234.	0.4	70

#	Article	IF	CITATIONS
55	Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness. Molecular Medicine, 2010, 16, 102-115.	1.9	69
56	Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival. Journal of Gastrointestinal Surgery, 2017, 21, 1226-1236.	0.9	69
57	Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology, 2009, 50, 752-762.	3.6	68
58	MicroRNAâ€425â€3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver International, 2015, 35, 1077-1086.	1.9	68
59	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. Hepatology, 2010, 52, 1723-1730.	3.6	67
60	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death and Disease, 2012, 3, e351-e351.	2.7	63
61	Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2012, 7, e46002.	1.1	63
62	Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget, 2016, 7, 54650-54661.	0.8	63
63	Hepatocellular nodules in cirrhosis: Focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transplantation, 2004, 10, S9-S15.	1.3	61
64	Expression and Mutational Status of c-kit in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2010, 5, 1447-1453.	0.5	61
65	The <i>HOX</i> gene network in hepatocellular carcinoma. International Journal of Cancer, 2011, 129, 2577-2587.	2.3	60
66	Insulinâ€like growth factorâ€l receptor and phosphorylated AKTâ€serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer, 2010, 116, 4686-4695.	2.0	59
67	Toker cells of the breast. Morphological and immunohistochemical characterization of 40 cases. Human Pathology, 2008, 39, 1295-1300.	1.1	58
68	Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death and Differentiation, 2011, 18, 1608-1616.	5.0	57
69	Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer, 2006, 6, 89.	1.1	56
70	Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. Oncolmmunology, 2017, 6, e1333215.	2.1	56
71	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. Liver Cancer, 2020, 9, 15-27.	4.2	56
72	Ultrasonography-detected macroregenerative nodules in cirrhosis: a prospective study. Gastroenterology, 1997, 112, 1617-1623.	0.6	55

#	Article	IF	Citations
73	Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. European Journal of Cancer, 2010, 46, 3383-3392.	1.3	55
74	Large liver cell dysplasia: A controversial entity. Journal of Hepatology, 2006, 45, 734-743.	1.8	54
75	Modulation of human Tâ€cell functions by reactive nitrogen species. European Journal of Immunology, 2011, 41, 1843-1849.	1.6	54
76	Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program. Clinical Cancer Research, 2008, 14, 1913-1919.	3.2	52
77	Liver precancerous lesions and hepatocellular carcinoma: The histology report. Digestive and Liver Disease, 2011, 43, S361-S372.	0.4	52
78	Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. PLoS ONE, 2014, 9, e95303.	1.1	52
79	Fractional allelic loss in non–end-stage cirrhosis: Correlations with hepatocellular carcinoma development during follow-up. Hepatology, 2000, 31, 846-850.	3.6	51
80	Presence of Twist1-Positive Neoplastic Cells in the Stroma ofÂChromosome-Unstable Colorectal Tumors. Gastroenterology, 2013, 145, 647-657.e15.	0.6	49
81	Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. International Journal of Cancer, 2016, 138, 983-991.	2.3	49
82	Identification of Potential Therapeutic Targets in Malignant Mesothelioma Using Cell-Cycle Gene Expression Analysis. American Journal of Pathology, 2009, 174, 762-770.	1.9	48
83	Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clinical and Molecular Hepatology, 2016, 22, 199-211.	4.5	48
84	Acinar cell cystadenocarcinoma of the pancreas: Report of rare case and review of the literature. Human Pathology, 2004, 35, 1568-1571.	1.1	47
85	The critical role of agrin in the hematopoietic stem cell niche. Blood, 2011, 118, 2733-2742.	0.6	47
86	Surgical Procedures in the DANTE Trial, A Randomized Study of Lung Cancer Early Detection with Spiral Computed Tomography: Comparative Analysis in the Screening and Control Arm. Journal of Thoracic Oncology, 2011, 6, 327-335.	0.5	46
87	Advanced precancerous lesions in the liver. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 269-284.	1.0	46
88	Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. , 1998, 34, 113-120.		45
89	Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 27-33.	4.2	44
90	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clinical Cancer Research, 2020, 26, 4381-4389.	3.2	44

#	Article	IF	CITATIONS
91	Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. Modern Pathology, 2016, 29, 283-292.	2.9	43
92	Gene methylation in pleural mesothelioma: Correlations with clinico-pathological features and patient's follow-up. Lung Cancer, 2008, 59, 369-376.	0.9	42
93	High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Laboratory Investigation, 2018, 98, 95-105.	1.7	41
94	Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. Journal of Hepatology, 2016, 64, 87-93.	1.8	40
95	A morphometric study of liver cell dysplasia. Human Pathology, 1988, 19, 471-474.	1.1	39
96	Abnormal p53 Expression in Lung Neuroendocrine Tumors Diagnostic and Prognostic Implications. Diagnostic Molecular Pathology, 1992, 1, 129-135.	2.1	39
97	Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation. Laboratory Investigation, 2002, 82, 729-736.	1.7	39
98	Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. British Journal of Cancer, 2001, 84, 196-198.	2.9	38
99	Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer, 2005, 48, 211-216.	0.9	38
100	Hepatocellular dysplastic nodules. Hepatology Research, 2007, 37, S125-S134.	1.8	35
101	The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination. Journal of Immunology, 2016, 196, 902-914.	0.4	35
102	Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection. Hepatology, 2003, 37, 72-78.	3.6	34
103	Activity of a specific inhibitor, gefitinib (Iressaâ,,¢, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Annals of Oncology, 2004, 15, 33-37.	0.6	34
104	Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer, 2013, 119, 266-276.	2.0	34
105	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1179-1187.	1.2	34
106	Liver cell dysplasia in cirrhosis. A serologic and immunohistochemical study. Cancer, 1986, 57, 1515-1521.	2.0	32
107	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. Journal of Gastrointestinal Surgery, 2019, 23, 2216-2224.	0.9	32
108	Thymic Tumor With Adenoid Cystic Carcinomalike Features. American Journal of Surgical Pathology, 2007, 31, 1161-1167.	2.1	31

#	Article	IF	CITATIONS
109	Re: Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. Journal of the National Cancer Institute, 2004, 96, 1402-1403.	3.0	30
110	Multiple focal nodular hyperplasias induced by oxaliplatin-based chemotherapy. World Journal of Hepatology, 2013, 5, 340.	0.8	30
111	Hepatocellular carcinoma: a clinical and pathological overview. Pathologica, 2021, 113, 203-217.	1.3	30
112	Laparoscopic lymphatic mapping and sentinel lymph node detection in colon cancer: technical aspects and preliminary results. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 1567-1571.	1.3	29
113	Patterns of integrin common chain \hat{l}^21 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. Journal of Pathology, 1993, 171, 5-11.	2.1	26
114	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Digestive and Liver Disease, 2015, 47, 432-435.	0.4	26
115	Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. Cancer, 1994, 74, 134-141.	2.0	24
116	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver International, 2015, 35, 2466-2473.	1.9	24
117	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Digestive and Liver Disease, 2013, 45, 43-49.	0.4	23
118	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE, 2016, 11, e0159612.	1.1	23
119	Frameshift Mutations of Human Gastrin Receptor Gene (hGARE) in Gastrointestinal Cancers with Microsatellite Instability. Laboratory Investigation, 2002, 82, 265-271.	1.7	21
120	Prostatic Stromal Tumor with Fatal Outcome in a Young Man: Histopathological and Immunohistochemical Case Presentation. Rare Tumors, 2010, 2, rt.2010.e57.	0.3	21
121	Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How. Frontiers in Medicine, 2017, 4, 10.	1.2	21
122	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 520-527.	0.5	19
123	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Frontiers in Oncology, 2018, 8, 181.	1.3	19
124	Cell Discohesion and Multifocality of Carcinoma In situ of the Bladder: New Insight From the Adhesion Molecule Profile (e-Cadherin, Ep-CAM, and MUC1). International Journal of Surgical Pathology, 2009, 17, 99-106.	0.4	17
125	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. American Journal of Pathology, 2019, 189, 2090-2101.	1.9	17
126	Molecular disorders in transitionalvs. peripheral zone prostate adenocarcinoma. International Journal of Cancer, 2001, 94, 383-389.	2.3	16

#	Article	IF	CITATIONS
127	A phosphokinomeâ€based screen uncovers new drug synergies for cancer driven by liverâ€specific gain of nononcogenic receptor tyrosine kinases. Hepatology, 2017, 66, 1644-1661.	3.6	15
128	A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development. American Journal of Pathology, 2018, 188, 785-794.	1.9	15
129	Nested stromal-epithelial tumour of the liver: An unusual liver entity. World Journal of Hepatology, 2014, 6, 155.	0.8	15
130	Radiological estimation of size in colorectal liver metastases: is it reliable? Comparison with post-resectional measurements. Updates in Surgery, 2010, 62, 21-26.	0.9	14
131	Anatomic Location of Breast Cancer Micrometastasis in Sentinel Lymph Node Predicts Axillary Status. Annals of Surgery, 2006, 243, 706-707.	2.1	13
132	Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. European Journal of Cancer, 2013, 49, 989-998.	1.3	12
133	Progressive Enrichment of Stemness Features and Tumor Stromal Alterations in Multistep Hepatocarcinogenesis. PLoS ONE, 2017, 12, e0170465.	1.1	12
134	Preneoplastic cellular changes in liver. Hepatology, 1998, 28, 1435-1435.	3.6	11
135	Phenotypic and molecular changes in noduleâ€inâ€nodule hepatocellular carcinoma with pathogenetic implications. Histopathology, 2018, 73, 601-611.	1.6	11
136	Hepatic Rosai-Dorfman Disease With Coincidental Lymphoma: Report of a Case. International Journal of Surgical Pathology, 2010, 18, 540-543.	0.4	10
137	Unclassified Renal Cell Carcinoma With Medullary Phenotype Versus Renal Medullary Carcinoma: Lessons From Diagnosis in an Italian Man Found to Harbor Sickle Cell Trait. Urology Case Reports, 2015, 3, 215-218.	0.1	10
138	Hepatocellular dysplastic nodules. Annali Italiani Di Chirurgia, 2008, 79, 81-9.	0.1	10
139	Cutaneous Melanoma Metastatic to Uterine Adenomyoma: Report of a Case. International Journal of Surgical Pathology, 2005, 13, 223-225.	0.4	9
140	CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study. Digestive and Liver Disease, 2017, 49, 434-439.	0.4	9
141	Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy. Liver International, 2018, 38, 303-311.	1.9	9
142	Development of a Deep-Learning Pipeline to Recognize and Characterize Macrophages in Colo-Rectal Liver Metastasis. Cancers, 2021, 13, 3313.	1.7	8
143	Immunohistochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pathology Research and Practice, 2005, 201, 71-81.	1.0	7
144	Cardiac hibernoma: a case report. Histopathology, 2012, 61, 985-987.	1.6	7

#	Article	IF	Citations
145	Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase. Journal of Experimental and Clinical Cancer Research, 2016, 35, 193.	3.5	7
146	Can Large Cell Change and High Proliferative Activity Predict Hepatocellular Carcinoma in Patients With Hereditary Hemochromatosis?. American Journal of Gastroenterology, 2000, 95, 2940-2945.	0.2	6
147	Cracking Spaces in Hashimoto Thyroiditis Are Lymphatic and Prelymphatic Vessels. American Journal of Surgical Pathology, 2010, 34, 1857-1861.	2.1	6
148	Non-Hormone-Induced Mixed Epithelial and Stromal Tumor of Kidney in a Man: Description of a Rare Case. Urology, 2008, 71, 168.e7-168.e9.	0.5	5
149	An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. International Journal of Biological Markers, 2015, 30, 73-80.	0.7	5
150	One-Step Nucleic Acid Amplification in Breast Cancer Sentinel Lymph Node: A Single Institutional Experience and a Short Review. Frontiers in Medicine, 2015, 2, 37.	1.2	5
151	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5
152	Expression of new phenotypic markers in cholangiocarcinoma and putative precursor lesions. Journal of Surgical Oncology, 1993, 53, 173-174.	0.8	4
153	Digital Pathology During the COVID-19 Outbreak in Italy: Survey Study. Journal of Medical Internet Research, 2021, 23, e24266.	2.1	4
154	Dante: A Randomised Trial on Early Diagnosis of Lung Cancer With Low-dose Spiral CT (LDCT); Initial Announcemen. Chest, 2003, 124, 118S.	0.4	3
155	DANTE: A RANDOMIZED STUDY ON LUNG CANCER SCREENING WITH LOW-DOSE SPIRAL CT (LDCT): END OF ACCRUAL AND PRELIMINARY RESULTS. Chest, 2006, 130, 114S.	0.4	2
156	Premalignant and Early Malignant Hepatocellular Lesions in Chronic Hepatitis/Cirrhosis. , 2018, , 487-505.		1
157	Integrin common chain \hat{l}^21 immunoreactivity in hepatocellular carcinoma. Journal of Pathology, 1994, 172, 363-364.	2.1	0
158	The "farmer―pathologist: a midsummer night's dream. Human Pathology, 2012, 43, 615-616.	1.1	0
159	Premalignant Hepatocellular Lesions. , 2011, , 457-472.		0
160	Effect of intratumoral CD3+ and NKp46+ cells on tumor progression in resected colorectal liver metastases treated with neoadjuvant chemotherapy Journal of Clinical Oncology, 2016, 34, 281-281.	0.8	0
161	Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma Journal of Clinical Oncology, 2020, 38, e17038-e17038.	0.8	0
162	The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication Journal of Clinical Oncology, 2020, 38, e17037-e17037.	0.8	0